{"id":"W3111161573","doi":"10.1002/onco.13628","title":"A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma","keywords":"Axitinib; Medicine; Renal cell carcinoma; Clinical endpoint; Internal medicine; Adverse effect; Population; Oncology; Phases of clinical research; Nausea; Gastroenterology; Urology; Pharmacology; Randomized controlled trial; Clinical trial; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003298951,0.00138124,0.002433695,0.0004423454,0.0005274769,0.001086087,0.0009685723,0.00191309,0.005252094],"category_scores_gemma":[0.002037289,0.0007093225,0.001807151,0.0004705121,0.001536573,0.001121044,0.0003759172,0.003881079,0.0008667756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001240543,"about_ca_system_score_gemma":0.002306797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00116192,"about_ca_topic_score_gemma":0.003373565,"domain_scores_codex":[0.9991089,0.0005024794,0.00004880136,0.0001301305,0.00007534033,0.000134239],"domain_scores_gemma":[0.9984641,0.0002875531,0.0003376594,0.0001413522,0.00009892399,0.0006704693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9358647,0.028125,0.002254204,0.0003915426,0.001072994,0.0001254187,0.0001002581,0.0008178768,0.007345208,0.0001731064,0.001595863,0.02213376],"study_design_scores_gemma":[0.8797808,0.1160607,0.002252886,0.00001227585,0.0001961668,0.00006402146,0.00001518899,0.0003896073,0.0004107256,0.0001158554,0.0006904621,0.00001136618],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863153,0.002516196,0.000664557,0.0009803774,0.0004663928,0.006090426,0.0009209285,0.00009591399,0.001949971],"genre_scores_gemma":[0.9842874,0.001632194,0.001675127,0.001667604,0.0005402164,0.005791783,0.001152795,0.00002582564,0.00322707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005252094,"threshold_uncertainty_score":0.01757002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0631375381713145,"score_gpt":0.3153081944287101,"score_spread":0.2521706562573955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}